Looking at AGN @ $2.47I like the tight float of AGN. Seems to be holding around $2.5 but some promising results from their DMT trials could get it moving again. Phase II trials could also start as early as next year on human stroke patients - will be something to look out for.
They recently commenced screening subjects for the Phase I DMT study which will identify the safety, tolerability, and pharmacokinetics of DMT. Preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor, an important part of brain recovery.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-screens-first-subject-120000046.html